Old Web
English
Sign In
Acemap
>
authorDetail
>
Kelly A. Arscott
Kelly A. Arscott
Trevena Inc
Tolerability
Medicine
Pharmacokinetics
Adverse effect
Pharmacology
2
Papers
13
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.
2020
CNS Drugs
Michael J. Fossler
Virginia D. Schmith
Stephen A. Greene
Lauren R. L. Lohmer
Michael S. Kramer
Kelly A. Arscott
I.E. James
Mark A. Demitrack
Show All
Source
Cite
Save
Citations (5)
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine
2019
Clinical pharmacology in drug development
Anne N. Nafziger
Kelly A. Arscott
Kristina Cochrane
Franck Skobieranda
David A. Burt
Michael J. Fossler
Show All
Source
Cite
Save
Citations (8)
1